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Case ReportsSimultaneous transapical transcatheter aortic and mitral valve
replacement in a high-risk patient with a previous mitral
bioprosthesisAdil H. Al Kindi, MD,a Khaled F. Salhab, MD,a Samir Kapadia, MD,b Eric E. Roselli, MD,a
Amar Krishnaswamy, MD,b Andrew Grant, MD,b Emin Murat Tuzcu, MD,b and Lars G. Svensson, MD,
PhD,a Cleveland, OhioDouble aortic and mitral valve replacement can now be per-
formed with acceptable perioperativemorbidity andmortal-
ity in experienced hands. However, some patients are
denied conventional surgery because of increased perioper-
ative risk. We present a patient with aortic and prosthetic
mitral stenosis who was at high risk for conventional
surgery that was managed with transcatheter aortic and
mitral valve replacement.
CLINICAL SUMMARY
A 76-year-old woman was transferred from an outside
institution with a 2-week history of weakness, nausea, and
shortness of breath (New York Heart Association class
III). She had hypertension, chronic obstructive pulmonary
disease (forced expiratory volume in 1 second 60% of pre-
dicted), severe pulmonary hypertension (pulmonary artery
systolic pressure 80 mm Hg), paroxysmal atrial fibrillationFIGURE 1. Simultaneous transapical TAVR and valve-in-valve replacement o
showing severe bioprosthetic mitral stenosis (arrow, left atrial view). B, Mitra
valve implantation.
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e90 The Journal of Thoracic and Cardiovascular Surgon warfarin, and a creatinine clearance of 36 mL/min. Her
surgical history included an aorta to innominate artery
bypass, mitral valve replacement for mitral stenosis with
a Carpentier-Edwards pericardial valve (size 25) (Edwards
Lifesciences Corp, Irvine, Calif) in 2003, and bilateral
carotid endarterectomy.
Echocardiography demonstrated normal left ventricular
function with a severely dilated left atrium, severe native
aortic valve stenosis with gradients of (peak/mean) 57/34
mm Hg, and a valve area of 0.44 cm2. The prosthetic mitral
valve showed severe stenosis due to prosthetic leaflet
thickening and calcification with gradients of 32/17 mm
Hg and trivial 1þ regurgitation (Figure 1, A). There was
also moderate to severe (3þ) tricuspid valve regurgitation.
Coronary angiography showed no significant disease.
Computed tomographic angiography showed severe diffuse
atherosclerotic disease of the thoracic and abdominal aorta
with calcification of the iliac and common femoral arteries.
The calculated logistic European System for Cardiac
Operative Risk Evaluation was 45.9%. She was symptom-
atic despite maximal medical management. Her surgical
risk for a conventional redo double-valve replacement
was extremely high. Therefore, the decision was made to
perform a transcatheter double-valve replacement via
a transapical approach.
The procedure was performed in a hybrid operating room
by a team consisting of cardiac surgeons, cardiologists, andf a failing bioprosthetic mitral valve. A, Intraoperative echocardiography
l valve after Sapien (Edwards Lifesciences Corp, Irvine, Calif) valve-in-
ery c September 2012
FIGURE 2. A, Fluoroscopic view after deploying the aortic valvewith thewire through the prostheticmitral valve (inducated by asterisk) (left anterior oblique
projection). B, Both valves in place (right anterior oblique projection). TAVR, Transcatheter aortic valve replacement;MV, mitral valve; ViV, valve-in-valve.
Case Reportsa cardiac anesthesiologist. Access to the left ventricular
apex was gained via a mini anterolateral thoracotomy
through the fifth intercostal space as determined by
computed tomography of the chest. Pledgeted purse-string
sutures were placed on the left ventricular apex. Preopera-
tive and intraoperative echocardiography confirmed that
the aortic annulus was 21 mm. After performing balloon
valvuloplasty of the aortic valve, a 23-mm Edwards Sapien
transcatheter heart valve (Edwards Lifesciences Corp) was
deployed in an antegrade fashion (Figure 2, A). Attention
was then turned to the mitral prosthesis. Awire was passed
through the prosthetic mitral valve, but no balloon valvulo-
plasty was performed. The inner internal diameter of the
mitral prosthesis on echocardiography was 23 mm. A
26-mm Edwards Sapien transcatheter heart valve was
deployed in a retrograde fashion as in the transfemoral
approach for the aortic valve (Figure 1, B). Both valves
were deployed under fluoroscopy and echocardiography
guidance confirming correct position (Figure 2, B). Postop-
erative echocardiography demonstrated trace paravalvular
leak and minimal valve gradients. After an initial prolonged
intubation, the patient continues to do well.DISCUSSION
In recent years, transcatheter aortic valve replacement
(TAVR)has emerged as a feasible and reproducible procedure
in high-risk patients. Small and large series demonstrated that
TAVR via the transapical approach has good results with ac-
ceptable morbidity and mortality.1 The outcomes are compa-
rable to the retrograde approach via the transfemoral artery.
With these successes, the use of TAVR has been
expanded to include patients who require redo valve re-
placement. Case reports and small series have shown the
feasibility of valve-in-valve replacement in both the aortic2
and mitral positions using a transcatheter valve that was
designed for the native aortic position.3 In the mitral posi-
tion, the presence of the prosthetic valve-sewing ring allows
anchoring of the percutaneous aortic valve.The Journal of Thoracic and CaIn this report, we demonstrate the successful simulta-
neous deployment of the Edwards Sapien transcatheter
heart valve in both the aortic andmitral positions. The aortic
valve was deployed successfully in the native aortic
annulus, and the mitral valve was a valve-in-valve deploy-
ment. Both deployed valves demonstrated excellent
post-deployment hemodynamics. Despite the patient’s
high-risk profile, she did well in the postoperative period.
CONCLUSIONS
The gold standard for the management of valve steno-
sis is valve replacement, including those who require re-
operations.4,5 However, high perioperative risk with
major morbidity and potential mortality outweighs the
symptomatic and survival benefit of a conventional
valve replacement in some patients. We show that
double-valve transcatheter replacement via the transapical
approach is technically feasible with the current available
technology. However, the results of this procedure must
be analyzed with caution because we do not yet have
mid- and long-term results of the durability and perfor-
mance of these valves when deployed simultaneously.
ADDENDUM
Six weeks after surgery, the patient developed gut gan-
grene, which she did not survive.
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